Tuesday 08 June 2021
Books – Syed Metwally
According to a new study published in the New England Journal of Medicine, on May 27, Pfizer vaccines given for 21 days to adolescents aged 12 to 15 years were safe and immunostimulating.
The study yielded 100% efficacy of the Pfizer vaccine against COVID-19 from 7 days after the second dose, according to timesofindia.
For the study, 2,260 adolescents aged 12 to 15 years were given 1,131 of the Pfizer vaccine, and 1,129 were given a placebo.
The study was conducted in the United States that already began vaccination for adolescents over the age of 12 in mid-May, after the Centers for Disease Control and Prevention approved the Pfizer vaccine for this age group.
Other countries that have approved the Pfizer vaccine for adolescents over 12 years of age include Chile, Canada, Japan and Italy, and Dubai and the Philippines have approved the vaccine for emergency use.
Of the 2,260 participants, 51 percent were male, 86 percent were white, and 12 percent were Hispanic. Overall, 1,308 participants had at least two months of follow-up after the second dose of vaccination.
Vaccine interactions (the degree to which a vaccine can produce an excessive immune response and negative reactions) and immunogenicity (the ability to elicit an immune response against pathogens) were compared with another group, of 16-25-year-olds.
In both age groups, headache and fatigue were the most commonly reported systemic events, after Pfizer, severe headache and fatigue were reported in a smaller proportion of participants aged 12-15 years compared to participants aged 16-25 years. The immune response to Pfizer in adolescents aged 12 to 15 was stronger compared to young adults aged 16 to 25, and the study said the vaccine’s observed efficacy was 100 percent.